← boardnext 2026-08-30next 2026-09-18next 2026-12-31next 2027-02-10next 2027-04-14next 2027-05-18next 2027-06-08next 2027-10-28next 2027-10-31next 2027-11-25next 2028-02-22next 2028-02-28next 2028-03-16next 2028-08-26next 2028-09-11next 2029-01-01next 2029-09-30next 2030-04-11
TKPHF
Takedadistress 1/10 · well-funded / low risk$34.50-1%today-12% from 52w high
Lead: Crohn's Disease · est. market ~$12B (approx, global)
Revenue
$4505720M
Liquidity
$1085679M
Runway
—
Shares 1y
0%
Price & events
+13.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.6%
1D
-0.6%
1W
+14.3%
1M
-0.1%
3M
+13.4%
6M
+27.4%
1Y
+38.9%
2Y
+25.6%
5Y
+19.5%
All
Overview
- Market Cap
- $53.74B
- Enterprise Value
- $3.83T
- Volume
- 90.50K
- 52 Week Range
- $26.44 – $39.20
- Total Shares
- 1.56B
- Float Shares
- 1.58B
- % Held by Insiders
- 0.03%
- % Held by Institutions
- 49.94%
- RVOL
- 5.42x
- Beta
- 0.09
Pipeline stages · 18 programs
Tetravalent Dengue Vaccine (TDV)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
TAK-360
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Maribavir
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Teduglutide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
TDV
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Zasocitinib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Vedolizumab IV
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Rusfertide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Dexlansoprazole
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
VONVENDI, ADVATE
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Show all 18 programs · 8 more ▾
Zasocitinib (Dose A)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Elritercept
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Mezagitamab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Fazirsiran Injection
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
IGI, 10%
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Idursulfase-IT, Elaprase
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Vortioxetine tablets
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Vonicog Alfa, ADVATE
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 61 trials · 60 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08-30 Estimated 50% readout ~2026-11-13 | Phase 3 | Tetravalent Dengue Vaccine (TDV) | Dengue Fever | — | active not recruiting |
| 2026-09-18 Estimated 50% readout ~2026-11-02 | Phase 2 | TAK-279 | Crohn's Disease | — | recruiting |
| 2026-09-30 Estimated 50% readout ~2026-11-14 | Phase 2 | TAK-279 | Ulcerative Colitis | — | active not recruiting |
| 2026-10-02 Estimated 50% readout ~2026-12-16 | Phase 3 | TAK-861 | Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy | — | recruiting |
| 2026-10-31 Estimated 50% readout ~2026-12-15 | Phase 1/2 | TAK-788 | Carcinoma, Non-Small-Cell Lung | — | active not recruiting |
Show all 61 trials · 56 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-10-31 Estimated 50% readout ~2027-01-14 | Phase 3 | TAK-788, Pemetrexed, Cisplatin | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | — | active not recruiting |
| 2026-12-31 Estimated 50% readout ~2027-03-16 | Phase 3 | Maribavir | Cytomegalovirus (CMV) | — | recruiting |
| 2027-01-18 Estimated 50% readout ~2027-04-03 | Phase 3 | Maribavir | Cytomegalovirus (CMV) | — | recruiting |
| 2027-02-10 Estimated 50% readout ~2027-04-26 | Phase 3 | Teduglutide | Short Bowel Syndrome | — | recruiting |
| 2027-03-16 Estimated 50% readout ~2027-05-30 | Phase 3 | TAK-755 | Thrombotic Thrombocytopenic Purpura (TTP) | — | active not recruiting |
| 2027-04-14 Estimated 50% readout ~2027-06-28 | Phase 3 | TDV | Dengue Fever | — | recruiting |
| 2027-05-18 Estimated 50% readout ~2027-08-01 | Phase 3 | Zasocitinib | Psoriatic Arthritis | — | recruiting |
| 2027-05-18 Estimated 50% readout ~2027-08-01 | Phase 3 | Zasocitinib, Active Comparator | Psoriatic Arthritis | — | recruiting |
| 2027-06-08 Estimated 50% readout ~2027-08-22 | Phase 3 | Vedolizumab, Upadacitinib | Crohn's Disease | — | recruiting |
| 2027-09-13 Estimated 50% readout ~2027-11-27 | Phase 3 | Vedolizumab IV | Crohn's Disease (CD) | — | recruiting |
| 2027-09-24 Estimated 50% readout ~2027-12-08 | Phase 3 | Vedolizumab IV | Moderately to Severely Active Ulcerative Colitis | — | active not recruiting |
| 2027-10-12 Estimated 50% readout ~2027-11-26 | Phase 2 | Zasocitinib | Nonsegmental Vitiligo | — | recruiting |
| 2027-10-28 Estimated 50% readout ~2027-12-12 | Phase 2 | Rusfertide | Polycythemia Vera | — | not yet recruiting |
| 2027-10-31 Estimated 50% readout ~2027-12-15 | Phase 2 | Dexlansoprazole | Gastroesophageal Reflux Disease (GERD) | — | active not recruiting |
| 2027-11-15 Estimated 50% readout ~2028-01-29 | Phase 3 | Vedolizumab IV, Vedolizumab SC | Ulcerative Colitis, Crohn's Disease | — | recruiting |
| 2027-11-25 Estimated 50% readout ~2028-02-08 | Phase 3 | VONVENDI, ADVATE | Von Willebrand Disease (VWD) | — | recruiting |
| 2027-11-28 Estimated 50% readout ~2028-01-12 | Phase 2 | TAK-360 | Narcolepsy Type 1 | — | recruiting |
| 2027-12-02 Estimated 50% readout ~2028-01-16 | Phase 2 | TAK-411 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | — | recruiting |
| 2027-12-06 Estimated 50% readout ~2028-01-20 | Phase 2 | TAK-755 | Acute Ischemic Stroke | — | recruiting |
| 2028-02-22 Estimated 50% readout ~2028-04-07 | Phase 2 | Zasocitinib (Dose A) | Hidradenitis Suppurativa | — | recruiting |
| 2028-02-28 Estimated 50% readout ~2028-04-13 | Phase 2 | Elritercept, Ruxolitinib | Myelofibrosis | — | recruiting |
| 2028-02-28 Estimated 50% readout ~2028-05-13 | Phase 2/3 | TAK-861 | Narcolepsy Type 1 | — | recruiting |
| 2028-03-16 Estimated 50% readout ~2028-05-30 | Phase 3 | Mezagitamab | Immune Thrombocytopenic Purpura (ITP) | — | recruiting |
| 2028-03-30 Estimated 50% readout ~2028-05-14 | Phase 2 | Zasocitinib | Crohn's Disease | — | not yet recruiting |
| 2028-05-01 Estimated 50% readout ~2028-07-15 | Phase 3 | Elritercept | Myelodysplastic Syndromes | — | recruiting |
| 2028-05-16 Estimated 50% readout ~2028-07-30 | Phase 3 | TAK-881 | Primary Immunodeficiency Diseases (PID) | — | active not recruiting |
| 2028-06-25 Estimated 50% readout ~2028-09-08 | Phase 3 | TAK-881, HYQVIA | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | — | recruiting |
| 2028-06-26 Estimated 50% readout ~2028-08-10 | Phase 2 | TAK-226 | Myelodysplastic Syndromes | — | not yet recruiting |
| 2028-08-26 Estimated 50% readout ~2028-11-09 | Phase 3 | Fazirsiran Injection | Alpha1-Antitrypsin Deficiency | — | recruiting |
| 2028-08-30 Estimated 50% readout ~2028-11-13 | Phase 3 | TAK-330, SOC 4F-PCC | Coagulation Disorder | — | recruiting |
| 2028-09-07 Estimated 50% readout ~2028-11-21 | Phase 3 | Mezagitamab | Kidney Disease | — | recruiting |
| 2028-09-11 Estimated 50% readout ~2028-11-25 | Phase 3 | IGI, 10% | Multiple Myeloma, Secondary Immunodeficiency | — | recruiting |
| 2028-11-01 Estimated 50% readout ~2029-01-15 | Phase 3 | TAK-928, Control Arm | IO-resistant sqNSCLC | — | recruiting |
| 2028-12-26 Estimated 50% readout ~2029-02-09 | Phase 1/2 | TAK-188 | Advanced or Metastatic Solid Tumors | — | recruiting |
| 2029-01-01 Estimated 50% readout ~2029-03-17 | Phase 2/3 | Idursulfase-IT, Elaprase | Hunter Syndrome | — | active not recruiting |
| 2029-01-15 Estimated 50% readout ~2029-03-01 | Phase 2 | Mezagitamab | Antibody-Mediated Rejection (AMR) | — | not yet recruiting |
| 2029-01-17 Estimated 50% readout ~2029-04-02 | Phase 3 | Fazirsiran Injection | Alpha1-Antitrypsin Deficiency | — | recruiting |
| 2029-04-30 Estimated 50% readout ~2029-07-14 | Phase 3 | Elritercept, Epoetin Alfa | Myelodysplastic Syndrome, Anemia | — | recruiting |
| 2029-07-29 Estimated 50% readout ~2029-10-12 | Phase 3 | Mezagitamab | Immune Thrombocytopenic Purpura (ITP) | — | recruiting |
| 2029-08-05 Estimated 50% readout ~2029-10-19 | Phase 3 | TAK-279 | Plaque Psoriasis | — | active not recruiting |
| 2029-09-30 Estimated 50% readout ~2029-12-14 | Phase 3 | Vortioxetine tablets | Major Depressive Disorder | — | recruiting |
| 2029-10-30 Estimated 50% readout ~2029-12-14 | Phase 2 | Elritercept | Myelodysplastic Syndromes, Cytopenia | — | recruiting |
| 2029-12-07 Estimated 50% readout ~2030-02-20 | Phase 3 | Elritercept | Myelofibrosis, Anemia | — | not yet recruiting |
| 2029-12-18 Estimated 50% readout ~2030-03-03 | Phase 3 | Zasocitinib | Psoriatic Arthritis | — | recruiting |
| 2029-12-30 Estimated 50% readout ~2030-02-13 | Phase 2 | Zasocitinib | Crohn's Disease, Ulcerative Colitis | — | recruiting |
| 2029-12-31 Estimated 50% readout ~2030-03-16 | Phase 3 | Vedolizumab, Concomitant Antibiotic Therapy | Pouchitis | — | recruiting |
| 2030-03-03 Estimated 50% readout ~2030-05-17 | Phase 3 | TDV | Dengue Fever | — | recruiting |
| 2030-03-08 Estimated 50% readout ~2030-05-22 | Phase 3 | Vedolizumab IV | Crohn's Disease | — | recruiting |
| 2030-04-11 Estimated 50% readout ~2030-06-25 | Phase 3 | Vonicog Alfa, ADVATE | Von Willebrand Disease (VWD) | — | recruiting |
| 2030-08-12 Estimated 50% readout ~2030-10-26 | Phase 3 | Vedolizumab SC | Ulcerative Colitis, Crohn's Disease | — | recruiting |
| 2030-08-18 Estimated 50% readout ~2030-10-02 | Phase 1/2 | TAK-505 | Malignant Solid Tumors | — | recruiting |
| 2031-06-15 Estimated 50% readout ~2031-08-29 | Phase 2/3 | TAK-360 | Idiopathic Hypersomnia, Narcolepsy Type 1, Narcolepsy Type 2 | — | recruiting |
| 2033-01-24 Estimated 50% readout ~2033-04-09 | Phase 3 | Zasocitinib | Plaque Psoriasis | — | recruiting |
| 2033-02-07 Estimated 50% readout ~2033-04-23 | Phase 3 | Vedolizumab IV | Ulcerative Colitis, Crohn's Disease | — | recruiting |
| 2033-05-02 Estimated 50% readout ~2033-07-16 | Phase 3 | Fazirsiran Injection | Alpha1-Antitrypsin Deficiency | — | active not recruiting |
| 2026-07-16 Estimated 50% readout ~2026-08-30 | Phase 2 | TAK-360 | Idiopathic Hypersomnia | — | recruiting |
Catalyst news & presentations · 1
- 2026-07-30Confirmed 100%earningsEarningsEarnings releaseyahoo
Approved drugs (14)
- ENTYVIOVEDOLIZUMAB2024 · Prescription
- EOHILIABUDESONIDE2024 · Prescription
- FRUZAQLAFRUQUINTINIB2023 · Prescription
- ENTYVIOVEDOLIZUMAB2023 · Prescription
- LIVTENCITYMARIBAVIR2021 · Prescription
- EXKIVITYMOBOCERTINIB SUCCINATE2021 · Discontinued
- MOTEGRITYPRUCALOPRIDE SUCCINATE2018 · Prescription
- MYDAYISAMPHETAMINE ASPARTATE2017 · Prescription
- ALUNBRIGBRIGATINIB2017 · Prescription
- VYVANSELISDEXAMFETAMINE DIMESYLATE2017 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — Crohn's Disease
Recent news
- 2026-07-21India approves its first dengue vaccine, from Japan's Takeda - Nikkei Asia
- 2026-07-21Lotte Giants End Takeda's Curse, Win 6-2 - 조선일보
- 2026-07-21Takeda (TAK) Secures Approval for First Dengue Vaccine in India - GuruFocus
- 2026-07-21Takeda's Dengue Vaccine (TAK-003) Becomes India's First Approved Dengue Vaccine, Bringing Prevention to One of the World's Most At-Risk Populations - Yahoo Finance
- 2026-07-20India’s first dengue vaccine approved: DCGI clears Takeda’s Qdenga for those aged 4 to 60 - The Indian Express
- 2026-07-20Biopharma bites: Scribe sets IPO terms, Takeda's dengue shot OKed in India - FirstWord PHARMA
- 2026-07-20Novartis and Takeda drugs gain rare blood cancer routine use on NHS - Pharmaceutical Technology
- 2026-07-20India gets first dengue vaccine as DCGI approves Takeda’s QDENGA | Hindustan Times - Hindustan Times
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.